Metastatik Kolorektal Kanserli Hastalarda Aflibercept Tedavisinin Etkinliği ve Güvenliği: Tek Merkez Deneyimi

Öz

Kolorektal kanser, dünya çapında en sık görülen malignitelerden birisidir ve sürekli olarak yeni tedavi seçenekleri ortaya sunulmaktadır. Bu çalışma, mevcut tedavi seçeneklerinden birisi olan aflibercept tedavisinin etki ve yan etkilerini göstermeyi amaçlamaktadır. Çalışmamıza Ocak 2014 ve Aralık 2020 tarihleri arasında Bursa Uludağ Üniversitesi Tıbbi Onkoloji Anabilim Dalı’nda kolorektal kanser tanısı almış 52 hasta dahil edildi. Bu hastaların tamamında tanı anında veya takiplerde gelişen metastaz mevcuttu. 2 hasta takip aralıklarının düzensiz olması nedeni ile çalışmadan çıkartıldı. Dahil edilen hastaların %74’ünde tanı anında metastaz mevcuttu ve %70’inde tümör sol kolon yerleşimliydi. Çalışma grubunun %56’sında KRAS mutasyonu saptandı. İkinci basamak tedavide en sık tercih edilen tedavi ajanı aflibercept olarak bulundu. İkinci ve sonraki basamaklarda aflibercept tedavisi almak arasında genel sağkalımda anlamlı fark izlenmedi. Yan etki profili ve sıklığı literatür ile uyumluydu, özellikle proteinüri açısından anlamlı fark saptandı.

Anahtar Kelimeler

• Metastatik kolorektal kanser
• Aflibercept
• VEGF inhibitörleri
• Proteinüri
• Yan etki

Efficacy and Safety of Aflibercept Treatment in Patients with Metastatic Colorectal Cancer: A Single-Center Experience

Öz

Colorectal cancer is one of the most common malignancies worldwide, and new treatment options are continually emerging. This study aimed to assess the effects and side effects of aflibercept, one of the current treatment options for the condition. We included fifty-two patients diagnosed with colorectal cancer at the Bursa Uludağ University Medical Oncology Department between January 2014 and December 2020. These patients either presented with metastasis at the time of diagnosis or developed it during follow-up and were subsequently treated with aflibercept. Two patients were excluded from the study due to irregular follow-up. Among the patients included, 74% had metastatic disease at diagnosis, and 70% had tumors located in the left colon. KRAS mutations were identified in 56% of the patients. Aflibercept was the most commonly preferred second-line treatment. The median progression-free survival (PFS) after treatment with aflibercept was 5.13 months, while the median overall survival (OS) was 11.9 months. No significant difference was observed in overall survival between patients receiving aflibercept as second-line treatment and those receiving it as later lines. The frequency of side effects was consistent with existing literature; notably, significant proteinuria was observed during treatment.

Anahtar Kelimeler

• Metastatic colorectal cancer
• Aflibercept
• VEGF inhibitors
• Proteinuria
• Side effects

Kaynakça

1. 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. 2. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64.
3. 3. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
4. 4. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5(1).
5. 5. Van Cutsem E, Cervantes A, Nordlinger B, et al. The ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(September):iii1–9.
6. 6. Patel A, Sun W. Ziv-afibercept in metastatic colorectal cancer. Biol Targets Ther. 2013;8:13–25.
7. 7. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85.
8. 8. Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res. 2013;19(8):1920/5

9. 9. Teng LS, Jin KT, He KF,et al. Clinical applications of VEGF-Trap (Aflibercept) in cancer treatment. J Chinese Med Assoc. 2010;73(9):449–56.
10. 10. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506.
11. 11. Piscitani L, Sirolli V, Di Liberato L, et al. Nephrotoxicity associated with novel anticancer agents (Aflibercept, dasatinib, nivolumab): Case series and nephrological considerations. Int J Mol Sci. 2020;21(14):1–18.
12. 12. Ivanova JI, Saverno KR, Sung J, et al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med Oncol. 2017;34(12):1–10.
13. 13. Syed YY, McKeage K. Aflibercept: A Review in Metastatic Colorectal Cancer. Drugs. 2015;75(12):1435–45.
14. 14. Fernández MA, Martínez LN, Covela RM, et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: prognostic and predictive markers. Cancer Med. 2019;8(3):882–9.
15. 15. Giordano G, Febbraro A, Venditti M, et al. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract. 2014;2014.
16. 16. Riechelmann RP, Srimuninnimit V, Bordonaro R, et al. Aflibercept plus FOLFIRI for second-line treatment of metastatic colorectal cancer: observations from the global aflibercept safety and health-related quality-of-life program (ASQoP). Clin Colorectal Cancer. 2019;18(3):183-191.e3.
17. 17. Erol C, Nahit Sendur MA, Bilgetekin I, et al. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. J Can Res Ther 2022;18:S347-53